About ScreenCell
ScreenCell is a Healthcare company based in Sarcelles (France) founded in 2011. It operates as a circulating tumor cells are isolated for oncology applications and analysis. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its competitors include Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
ScreenCell was established in 2011 in Sarcelles, France, within the biotechnology sector focused on oncology. Devices for capturing circulating tumor cells are produced, allowing isolation of viable cells from blood samples. These tools support molecular analysis, cell culturing, counting, and morphological assessment without requiring new interfaces for standard in-vitro diagnostic systems. CE-marked products are applied in research, clinical trials, hospitals, and clinics across Europe.
- Headquarters Sarcelles, France
- SectorsHealthcare
- Website screencell.com/en
- Social LinkedIn
- Latest Funding Round$390.64K (USD), Grant
Jan 2017
- Investors
Funding Insights of ScreenCell
- Total Rounds 3
- Last Round Grant — $390,642
- First Round $1.9M
(Oct 2014)
- Investors Count 1
All 3 funding rounds of ScreenCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $390,642 | Grant | – | – | |
| Jan 2016 | $350,235 | Grant | – | – | |
| Oct 2014 | $1.9M | Grant | – | – | – |
1 investors in total: 1 institutional.
Investors in ScreenCell
ScreenCell has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for ScreenCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ScreenCell
3 dated milestones of ScreenCell across 6 years, from founding to its latest funding, stage changes and deals.
- Founded ScreenCell is founded.
- Funding First funding round of $1.9M.
- Funding Latest funding round, Grant, of $391K.
Competitors of ScreenCell
ScreenCell has 9 listed competitors in our database, 9 of them funded. They include Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | – | Provider of DNA sequencing for cancer detection | |
| billiontoone.com | 2015 | San Francisco, United States | $388.62M | 47 | Provider of cell-free cancer liquid biopsy test |
Detailed competitors of ScreenCell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ScreenCell
The website of ScreenCell (screencell.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 139.4% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as ScreenCell (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Screencell
Complete news archive for ScreenCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ScreenCell
ScreenCell was founded in 2011 and raised its 1st funding round 3 years after it was founded.
ScreenCell is headquartered in Sarcelles, France.
ScreenCell was established in 2011 in Sarcelles, France, within the biotechnology sector focused on oncology. Devices for capturing circulating tumor cells are produced, allowing isolation of viable cells from blood samples. These tools support molecular analysis, cell culturing, counting, and morphological assessment without requiring new interfaces for standard in-vitro diagnostic systems. CE-marked products are applied in research, clinical trials, hospitals, and clinics across Europe.
ScreenCell's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
ScreenCell has 1 investor. Key investors include European Union.